Physicians are harboring concerns that the Trump Administration’s recently-announced plans to revamp prescription drug pricing will harm patient care access, increase patient costs, and reduce overall care quality, according to a survey conducted by the Community Oncology Alliance (COA).
The Trump Administration recently announced a blueprint for reforming prescription drug prices with the end goal of reducing out-of-pocket costs for patients. The blueprint notably included calls for better price transparency from prescription drug manufacturers.
Read Next
